CD8A and neoplasm: Although CHI (including PDCD1 blockade or anti-CTLA4) in patients with dMMR/MSI-H mCRC significantly increase the antitumor activity of tumor specific CD8+ T-cells with highly durable tumor response, they are associated with virtually no activity in patients with pMMR/non-MSI-H mCRC (51, 52).